Latest Psilocin Pharma News
Oct 12, 2021
Michael Frank, CEO of Revive Therapeutics, and Derrick Welsh, COO of Psilocin Pharma, a division of Revive Therapeutics, discuss clinical research investigating novel treatment targets for psilocybin, such as treatment-resistant depression in patients with cancer.
Psilocin Pharma Frequently Asked Questions (FAQ)
What is Psilocin Pharma's latest funding round?
Psilocin Pharma's latest funding round is Acquired.
Who are the investors of Psilocin Pharma?
Investors of Psilocin Pharma include Revive Therapeutics.